On March 18, 2026 Ipsen (Euronext: IPN; ADR: IPSEY) reported the presentation of new preclinical data across multiple early development programs currently in Phase I clinical trials, at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) congress. These latest data include an oral presentation for T cell activator (TCA) IPN01203 to be presented during the coveted New Drugs on the Horizon program session, highlighting the differentiated mode of action, activating Vβ6/Vβ10 T cells. These latest preclinical data will expand the growing evidence base, reinforcing the first-in-class potential of IPN01203 to improve outcomes where there are significant unmet needs for people living with solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Additionally, Ipsen revealed ITGA2 as the novel target for innovative antibody-drug conjugate (ADC) IPN60300, now in active Phase I evaluation. Preclinical findings showed pronounced over-expression of ITGA2 across multiple solid tumors—including pancreatic, gastric and colorectal cancers—with clear differential expression when compared to normal tissues. These results confirmed that IPN60300 binds specifically and with high affinity to ITGA2, enabling efficient internalization and accumulation of the exatecan payload. Further preclinical tumor model data showed dose-dependent anti-tumor activity and favorable tolerability, suggesting a promising first-in-class therapy with the potential to improve clinical outcomes.
"These data presented at AACR (Free AACR Whitepaper) exemplify our approach to early science, showcasing how we are harnessing precision immuno-modulation backed by the strength of preclinical data to advance next generation therapies where there are the highest unmet needs," said Mary Jane Hinrichs, SVP Early Development, Ipsen. "It’s a privilege to see the growing transformative potential of these new modalities, paving the way for potential best- and first-in-class impact for people living with cancer."
Underscoring the strength and promise of Ipsen’s precision medicine approach, IPN01203 and IPN60300 combine precision targeting with innovative mechanisms of action with the aim of delivering strength of efficacy where few other treatments exist.
About IPN01203
IPN01203 is a first-in-class T cell activator which selectively activates a group of Vβ6 T cells through the TCR and IL-15R pathways, enhancing their ability to recognize and target tumors. IPN01203 was generated by Marengo’s Selective T Cell Activation Repertoire (STAR) platform, a multi-specific fusion protein library that targets specific TCR Vβ variants fused to different co-stimulate moieties to develop potent T cell activators. A Phase I/II dose escalation and expansion trial is ongoing.
About IPN60300
IPN60300 is a first-in-class antibody-drug conjugate targeting the novel tumor antigen ITGA2 known to be overexpressed in many solid tumors, including pancreatic, gastric and colorectal cancers. This novel tumor antigen was identified using Foreseen’ Biotechnology’s high throughput, integrated translational proteomics, and artificial intelligence (AI)-powered screening platforms. Comprised of an ITGA2-targeting antibody, exatecan payload and innovative linker from Escugen Biotechnology’s EZWi-Fit, IPN60300 is optimally designed to allow for a wide therapeutic index, with potential for improved efficacy over standard of care as well as a favorable safety profile. A Phase I/II dose escalation and expansion trial is ongoing.
(Press release, Ipsen, MAR 18, 2026, View Source [SID1234663702])